

ESTUDIO DE ESTABILIDAD

ATORVASTATINA COMPRIMIDOS RECUBIERTOS 20 mg

Atorvastatina Cálcica (Forma Cristalina)

Subdepartamento Registros y Autorizaciones Sanitarias

ATORVASTATINA COMPRIMIDOS RECUBIERTOS 20 mg Estudio de estabilidad

Contenido

I.	PROTOCOLO	2
1.	. Condiciones	2
2.	. Tipo de envase	2
3.	. Fecha de inicio y fin del estudio de estabilidad	2
4.	. Análisis realizados y frecuencia de testeo:	3
5.	. Especificaciones del producto terminado	4
II.	FÓRMULA CUALI-CUANTITA	5
III.	RESULTADOS	7
1.	. Estudio de estabilidad Acelerado	7
2.	. Estudio de estabilidad a tiempo real	. 13
IV.	DISCUSIÓN	. 22
٧.	CONCLUSIÓN	. 22
VI.	ESPECIFICACIÓN DE LA VIDA ÚTIL	. 22



I. PROTOCOLO

Se realizó una evaluación de la estabilidad de tres lotes de ATORVASTATINA COMPRIMIDOS RECUBIERTOS 20 mg fabricados por Emil Pharmaceutical Industries Pvt. Ltd., utilizando materia prima suministrada por Morepen Laboratories Ltd. El estudio se llevará a cabo a dos tiempos y condiciones ambientales.

A continuación los lotes a analizar:

Número de lote	Fecha de manufactura	Tamaño de lote
MD748	Octubre 2018	100.000 (Comp. Rec.)
MD749	Octubre 2018	100.000 (Comp. Rec.)
MD750	Octubre 2018	100.000 (Comp. Rec.)

1. Condiciones

El estudio se realizó almacenando muestras, en las siguientes condiciones de temperatura y humedad relativa:

	Estudio Acelerado	Estudio a tiempo real
Temperatura	40°C ± 2°C	30°C ± 2°C
Humedad	75 % ± 5 % H. R.	65 % ± 5 % H. R

2. Tipo de envase

Estuche de cartulina impresa que contiene Blíster ALU/PVC transparente, más folleto de información al paciente, todo debidamente rotulado y sellado.

3. Fecha de inicio y fin del estudio de estabilidad

- Fecha de inicio: El estudio se inició en Octubre 2018

- Fecha de término: El estudio aún sigue en curso.



4. Análisis realizados y frecuencia de testeo:

a) Estudio acelerado

Parámetros medidos	Inicial	3 meses	6 meses
Descripción	٧	٧	٧
Identificación	٧	-	٧
Peso Promedio	٧	-	٧
Desintegración	٧	٧	٧
Disolución	٧	٧	٧
Uniformidad de dosis	٧	-	٧
Impurezas orgánicas	٧	٧	٧
Valoración	٧	٧	٧
Recuento microbiano	٧	٧	٧

b) Estudio a tiempo real

Parámetros medidos	Inicial	3 M	6 M	9 M	12 M	18 M	24 M	36 M	39 M
Descripción	٧	٧	٧	٧	٧	٧			
Identificación	٧	-	-	-	-	-			
Peso Promedio	٧	-	-	-	-	-			
Desintegración	٧	٧	٧	٧	٧	٧			
Disolución	٧	٧	٧	٧	٧	٧			
Uniformidad de dosis	٧	-	-	-	-	-			
Sustancias	٧	٧	٧	٧	٧	٧			
Relacionadas									
Valoración	٧	٧	٧	٧	٧	٧			
Recuento microbiano	٧	٧	٧	٧	٧	٧			

NOTA: V = Parámetro debe ser medido.

Cabe destacar que la metodología utilizada para la medición de los diferentes parámetros en el estudio de estabilidad del producto ATORVASTATINA COMPRIMIDOS RECUBIERTOS 20 mg es la misma declarada en la metodología original para el análisis del producto terminado.



^{*} Estudio en curso, se informará actualización oportunamente.

5. <u>Especificaciones del producto terminado para estabilidad:</u>





TITLE	Protocol No. : QA/STB/F1007-S00
TITLE Atorvastatin Tablet 20 mg	Revision No. : 00
Atorvastatii Taolet 20 mg	Page No. : 7 of 10

11. Drug product specification:

Sr. No.	Test	Specification	
1	Description	White to off white biconvex film coated tablets plain on both sides.	
2	Identification	The retention time of the major peak of the sample solution corresponds to that of the standard solution, as obtained in the Assay.	
3	Average Weight	176.7 mg to 195.3 mg	
4	Disintegration Time	N.M.T 15 minutes	
5	Dissolution	N.L.T. 80% (Q) of labeled amount dissolved in 15 minutes	
6	Uniformity of Dosage Units	NMT 15.0 When determined on 10 individual units	
		Atorvastatin Pyrrilidone Analog: NMT 0.5%	
		Atorvastatin Related Compound H: NMT 1.0%	
	Organic Impurities	Atorvastatin epoxy pyrroloxazin 6 hydroxy analog: NMT 0.5%	
		Atorvastatin epoxy pyrroloxazin 7 hydroxy analog: NMT 0.5%	
7		Atorvastatin epoxy THF analog: NMT 0.25%	
		Atorvastatin related compound D: NMT 0.35 to 0.5 (if	
		Atorvastatin epoxy THF anlog is integrated together)	
		Any other unspecified degradation product: NMT 0.2%	
		Total degradation: NMT 4.0%	
8	Assay	94.5% to 105.0%	
Microbia	ıl Limit Test		
Total aer	obie microbial counts:		
8	Bacterial Counts	N.M.T 1000 cfu/ gm	
9	Fungi	N.M.T 100 cfu/ gm	
Test for S	specified microorganisms		
10	Escherichia Coli	Absent in 1 gm	
11	Salmonella	Absent in 10 gm	
12	Pseudomonas aeruginosa	Absent in 1 gm	
13	Staphylococcus aureus	Absent in 1 gm	



FÓRMULA CUALI-CUANTITATIVA II.









TITLE	DOCUMENT NUMBER	BMR-T993-S01-M
	ISSUE DATE	Mar 2019
ATORVASTATIN TABLET 20 mg	REVISION DATE	Feb 2022

COMPOSITION OF PRODUCT

Sr. No.	Constituent	Specification	Quantity Per Tab (mg)	USE
1	Atorvastain Calcium*	USP	20.68	Medicament
2	Microcrystalline cellulose	BP	94.62	Diluent
3	Lactose BP(30#)	BP	60.60	Diluent
4	Croscarmellose Sodium	USP	2.10	Disintegrating agent
5	Magnesium Stearate	BP	2.00	Lubricant
BAS	E COATING			
6	Ready mix Moistshield**	IHS	2.00	Base Coating agent
7	Isopropyl Alcohol***	BP		Solvent
8	Methylene Chloride ***	BP	-	Solvent
FIL	M COATING			
9	Ready Mix white **	IHS	4.00	Coating agent
10	Purified Water***	BP	-	Solvent

Note:
*1.034 mg Atorvastatin Calcium — 1 mg of Atorvastatin.
Therefore, 20.68 mg Atorvastatin Calcium — 20 mg of Atorvastatin base at 100 % assay.

- ** About 30 % weight loss during coating
 *** Does not remain in final formulation

IHS: In house USP United state pharmacopoeia:41, NF: National Formulary 36 BP: British Pharmacopoeia:2017

Proposed by: Mr. M R. Patil Production Officer Date: 19/02/19

Mr. D. Damos han Production Manager Date: 20 | 02-|19 Approved by:
Approved by:
Mr. S. M. Daptardar
QA Manager
Date: 21/2/19



ATORVASTATINA COMPRIMIDOS RECUBIERTOS 20 mg

Estudio de estabilidad



TITLE	DOCUMENT NUMBER	BMR-T993-S01-M
A CONTRACTOR A STREET OF A STREET OF A STREET	ISSUE DATE	Mar 2019
ATORVASTATIN TABLET 20 mg	REVISION DATE	Feb 2022

Composition for Ready Mix Moistshield:

Sr. No.	Ingredients	CI number
1	Hydroxy Propyl Methyl Cellulose	
2	Diethyl Phthalate	12
3	Ethyl Cellulose	
4	Talc	
4	Titanium Dioxide	77891

Composition for Colour Ready Mix white:

Sr. No.	Ingredients	CI number
1	Hypromellose	-
2	Polyethylene Glycol / Macrogol	•
3	Titanium Dioxide	77891

Prepared by: Mr. M R. Patil Production Officer Date: 1911/2/19

Checked by: Mr. D.Damoshan Production Manager Date: 26 | 12/19 Approved by:
Mr. S/M. Daptardar
QA Manager
Date: 21/2/19



III. **RESULTADOS**

a) Estudio de estabilidad acelerado:



	ACCELER	ATED STABILE	TY S	TUDY REPORT	
Name of Product	Atorvastatin Tabl			tch No.	MD748
Description of the pack	10's Alu-PVC Bl	ister pack	Mfg	. Date	Oct 2018
Parameters and test method monitored	Description, Iden Average weight, I Dissolution, Unif	D.T.,	Exp	oiry Date	Sept 2021
method monitored	Dosage Units, Or Assay and MLT.	ganic Impurities,	Sto	rage Conditions	40°C ± 2°C and 75% ± 5% RH
Date of Initiation	Oct 2018		Dat	e of completion	Apr 2019
TEST	LIMITS		RE	SULTS OF ANALY	
	**************************************	Initial		3 months	6 months
December	White to off white biconvex film	White to off whi biconvex film	te	White to off white biconvex film	White to off white biconvex film
Description	coated tablets plain	coated tablets pl	ain	coated tablets plain	coated tablets plain
	on both sides.	on both sides.		on both sides.	on both sides.
	The retention time	The retention tin			The retention time
	of the major peak in the	of the major pea in the	k		of the major peak in the
	chromatogram of	chromatogram o	f		chromatogram of
	assay preparation	assay preparation			assay preparation
Identification	corresponds to that	corresponds to ti		_	corresponds to that
	of the standard	of the standard			of the standard
	preparation obtained as directed	preparation obtained as direc			preparation obtained as directed
		in the assay for	tea		
	in the assay for Atorvastatin.	Atorvastatin			in the assay for Atorvastatin.
A Weigh	176.7 mg to 195.3				
Average Weight	mg	186.12 mg		-	187.05 mg
D.T.	NMT 15 min	1 min		1 min	1 min
	NLT 80% (O)	1] 94.65% 2] 93.14% 3] 92.49%		1] 93.54% 2] 91.60% 31 90.74%	1] 92.90% 2] 92.46% 3] 92.68%
Dissolution	dissolved in 15 min	41 90.98%		41 94.19%	41 90.74%
		5] 93.14%		5] 92.25%	5] 90.96%
		6] 93.57%		6] 92.90%	6] 91.17%
Uniformity of dosage units	NMT 15.0 When determined on 10 individual units	1.9		-	2.1
Organic Impurities					
Atorvastatin Pyrrilidone Analog	NMT 0.5%	0.077%		0.079%	0.080%
Atorvastatin Related Compound H	NMT 1.0%	0.168%		0.170%	0.171%
Atorvastatin epoxy					
pyrroloxazin 6 hydroxy analog	NMT 0.5%	0.026%		0.025%	0.029%
Atorvastatin epoxy pyrroloxazin 7 hydroxy analog	NMT 0.5%	Not Detected		Not Detected	Not Detected
Atorvastatin epoxy THF analog	NMT 0.25%	0.010%		0.013%	0.016%





			TY STUDY REPORT	E application
Name of Product	Atorvastatin Table	rts 20 mg	Batch No.	MD748
Description of the pack	10's Alu-PVC Bla	ster pack	Mfg. Date	Oct 2018
Parameters and test	Description, Identi Average weight, Dissolution, Unifo	ET.	Expiry Date	Sept 2021
method monitored	Dosage Units, Org Assay and MLT		Storage Conditions	40°C ± 2°C and 75% ± 5% RH
Date of Initiation	Oct 2018	,	Date of completion	Apr 2019
TEST	LIMITS		RESULTS OF ANAL	
1531	Limits	Initial	3 months	6 months
Atorvastatin related compound D	NMT 0.35 to 0.5 (if Atorvastatin epoxy THF anlog is integrated together)	Not Detected	i Not Detected	Not Detected
Any other unspecified degradation product	NMT 0.2%	0.083%	0.088%	0.092%
Total degradation:	NMT 4.0%	0.370%	0.384%	0.411%
Assay	94.5% to 105.0%	99.87%	99.35%	98.89%
Microbial Limit Tes	it	177770000		
Total aerobic micro	bial count			
Bacterial Counts	NMT 1000 cfu' gm	35 cfug	35 cfu.g	40 cfu/g
Fungi	NMT 100 cfu/ gm	Absent	Absent	Absent
Test for specified m		I masking		
E. Coli	Absent in 1 gm	Absent	Absent	Absent
Absent	Absent in 10 gm	Absent	Absent	Absent
Pseudomonas	Absent in 1 gm	Absent	Absent	Absent
Stap, aureus	Absent in 1 gm	Absent	Absent	Absent







Reg office: 101 Istangatara, Kulupwadi, Borinat Esat, Murebai 480056, INDA. Tel: +61-02-4290006 Email: info@cellpframea.ii



ACCELERATED STABILITY STUDY REPORT

	1				
Name of Product	Atorvastatin Table	ets 20 mg	Bat	ch No.	MD749
Description of the pack	10's Alu-PVC Bli	•	Mf	g. Date	Oct 2018
Parameters and test	Description, Ident Average weight, I Dissolution, Unife	D.T.,	Exp	oiry Date	Sept 2021
method monitored	Dosage Units, Org Assay and MLT.		Sto	rage Conditions	40°C ± 2°C and 75% ± 5% RH
Date of Initiation	Oct 2018			e of completion	Apr 2019
TEST	LIMITS		RF	SULTS OF ANALY	SIS
11231	LIMITS	Initial		3 months	6 months
Description	White to off white biconvex film	White to off whi biconvex film	_	White to off white biconvex film	White to off white biconvex film
	coated tablets plain on both sides.	coated tablets pl on both sides.		coated tablets plain on both sides.	coated tablets plain on both sides.
Identification	The retention time of the major peak in the chromatogram of assay preparation corresponds to that of the standard preparation obtained as directed in the assay for Attorvastatin.	The retention tin of the major peak in the chromatogram of assay preparation corresponds to til of the standard preparation obtained as direct in the assay for	k f n hat	-	The retention time of the major peak in the chromatogram of assay preparation corresponds to that of the standard preparation obtained as directed in the assay for
Average Weight	Atorvastatin. 176.7 mg to 195.3	Atorvastatin. 187.15 mg		_	Atorvastatin. 186.45 mg
	mg				
D.T.	NMT 15 min	2 min		1 min	l min
Dissolution	NLT 80% (Q) dissolved in 15 min	1] 93.51% 2] 94.16% 3] 92.65% 4] 94.16% 5] 94.59% 6] 94.80%		1] 92.70% 2] 92.70% 3] 93.12% 4] 93.98% 5] 94.41% 6] 93.98%	1] 93.76% 2] 92.68% 3] 92.25% 4] 92.90% 5] 90.74% 6] 92.25%
Uniformity of dosage units	NMT 15.0 When determined on 10 individual units	1.6		-	1.9
Organic Impurities					
Atorvastatin Pyrrilidone Analog	NMT 0.5%	0.069%		0.071%	0.079%
Atorvastatin Related Compound H	NMT 1.0%	0.167%		0.166%	0.170%
Atorvastatin epoxy pyrroloxazin 6 hydroxy analog	NMT 0.5%	0.021%		0.026%	0.029%
Atorvastatin epoxy pyrroloxazin 7 hydroxy analog	NMT 0.5%	Not Detected	l	Not Detected	Not Detected
Atorvastatin epoxy THF analog	NMT 0.25%	0.011%		0.013%	0.015%





Reg office: 101 Manapator: Kintania di Bonest Cast Murrius 400366: N(DA) Te: +01-22-42950000 Erras ortogenistrania in



Atorvastatin Tablet	ts 20 mg	Batch No.	MD749
10's Alu-PVC Blis	ter pack	Mfg. Date	Oct 2018
Average weight, D	T.,	Expiry Date	Sept 2021
		Storage Conditions	40°C ± 2°C and 75% ± 5% RH
Oct 2018		Date of completion	Apr 2019
LOUTE		RESULTS OF ANAL	YSIS
Limits	Initial	3 months	6 months
NMT 0.35 to 0.5 (if Atorvastatin epoxy THF anlog is integrated together)	Not Detected	I Not Detected	Not Detected
NMT 0.2%	0.089%	0.090%	0.096%
NMT 4.0%	0.360%	0.378%	0.405%
94.5% to 105.0%	99.85%	99.22%	98.88%
t i			
oial count			CALL ATATISANS
NMT 1000 cfu/ gm	45 cfu/g	45 cfu/g	45 cfu/g
NMT 100 cfu/ gm	Absent	Absent	Absent
Absent in 1 gm	Absent	Absent	Absent
Absent in 10 gm	Absent	Absent	Absent
Absent in 1 gm	Absent	Absent	Absent
Absent in 1 gm	Absent	Absent	Absent
	Atorvastatin Tablei 10's Alu-PVC Blis Description, Identii Average weight, D Dissolution, Unifor Dosage Units, Orga Assay and MLT Oct 2018 LIMITS NMT 0.35 to 0.5 (if Atorvastatin epoxy THF anlog is integrated together) NMT 0.2% NMT 4.0% 94 5% to 105 0% iolal count NMT 1000 cfu/ gm NMT 1000 cfu/ gm NMT 100 cfu/ gm Croorganisms: Absent in 1 gm Absent in 10 gm	Atorvastatin Tablets 20 mg	10's Alu-PVC Blister pack Mfg. Date







Reg office: 101 Mangelors, Kulupvesti, Borisal Esat, Murribet 460056, INDIA. Tel: +01-02-4290098 Ernati info@poretphama.in



ACCELERATED STABILITY STUDY REPORT

Name of Product	Atorvastatin Tabl	ets 20 mg	Bat	tch No.	MD750
Description of the pack	10's Alu-PVC Bli	ister pack	Mf	g. Date	Oct 2018
Parameters and test	Description, Ident Average weight, I Dissolution, Unifo	D.T.,	Exp	piry Date	Sept 2021
method monitored	Dosage Units, Or Assay and MLT.		Stor	rage Conditions	40°C ± 2°C and 75% ± 5% RH
Date of Initiation	Oct 2018		Dat	te of completion	Apr 2019
TEST	1700		RE	SULTS OF ANALY	SIS
TEST	LIMITS	Initial		3 months	6 months
Description	White to off white biconvex film	White to off whi biconvex film	_	White to off white biconvex film	White to off white biconvex film
Description	coated tablets plain on both sides.	coated tablets pla on both sides.		coated tablets plain on both sides.	coated tablets plain on both sides.
Identification	The retention time of the major peak in the chromatogram of assay preparation corresponds to that of the standard preparation obtained as directed in the assay for Attorvatatin.	The retention tin of the major peal in the chromatogram o assay preparation corresponds to to of the standard preparation obtained as direc in the assay for Atoryastatin	f n nat	-	The retention time of the major peak in the chromatogram of assay preparation corresponds to that of the standard preparation obtained as directed in the assay for Attorvastatin.
Average Weight	176.7 mg to 195.3 mg	188.01%		-	186.12%
D.T.	NMT 15 min	1 min		1 min	1 min
Dissolution	NLT 80% (Q) dissolved in 15 min	1] 94.80% 2] 95.23% 3] 92.44% 4] 93.51% 5] 94.16% 6] 93.30%		1] 92.91% 2] 91.84% 3] 92.27% 4] 92.05% 5] 93.77% 6] 92.27%	1] 92.68% 2] 92.46% 3] 92.25% 4] 92.90% 5] 90.74% 6] 90.96%
Uniformity of dosage units	NMT 15.0 When determined on 10 individual units	1.9		-	2.5
Organic Impurities					
Atorvastatin Pyrrilidone Analog	NMT 0.5%	0.074%		0.077%	0.081%
Atorvastatin Related Compound H	NMT 1.0%	0.160%		0.169%	0.175%
Atorvastatin epoxy pytroloxazin 6 hydroxy analog	NMT 0.5%	0.027%		0.021%	0.031%
Atorvastatin epoxy pyrroloxazin 7 hydroxy analog	NMT 0.5%	Not Detected		Not Detected	Not Detected
Atorvastatin epoxy THF analog	NMT 0.25%	0.015%		0.020%	0.024%





			TY STUDY REPORT	
Name of Product	Atorvastatin Table	ts 20 mg	Batch No.	MD750
Description of the pack	10's Alu-PVC Blis	ter pack	Mfg. Date	Oct 2018
Parameters and test	Description, Identi Average weight, D Dissolution, Unifo	T.	Expiry Date	Sept 2021
method monitored	Dosage Units, Org Assay and MLT		Storage Conditions	40°C ± 2°C and 75% ± 5% RH
Date of Initiation	Oct 2018		Date of completion	Apr 2019
TEST	LIMITS		RESULTS OF ANAL	YSIS
16.51	Lastins	Initial	3 months	6 months
Atorvastatin related compound D	NMT 0.35 to 0.5 (if Atorvastatin epoxy THF anlog is integrated together)	Not Detected	1 Not Detected	Not Detected
Any other unspecified degradation product	NMT 0.2%	0.082%	0.086%	0.089%
Total degradation:	NMT 4.0%	0.374%	0.395%	0.415%
Assay	94.5% to 105.0%	99.56%	99.11%	98.86%
Microbial Limit Te	st			
Total aerobic micro	bial count		to to the same of	1.6 0000 P.C. T
Bacterial Counts	NMT 1000 efu/ gm	30 cfu/g	35 cfu/g	35 cfu/g
Fungi	NMT 100 cfu/ gm	Absent	Absent	Absent
Test for specified m				
E. Coli	Absent in 1 gm	Absent	Absent	Absent
Salmonellae	Absent in 10 gm	Absent	Absent	Absent
Pseudomonas	Absent in 1 gm	Absent	Absent	Absent
Stap. Aureus	Absent in 1 gm	Absent	Absent	Absent





b) Estudio de estabilidad a tiempo real:


PHARMACEUTICAL PROBLEM PHARMACEUTICAL PROBLEM PHARMACEUTICAL PHARMACEUTICAL PHARMACEUTICAL PHARMACEUTICAL PROBLEM PHARMACEUTICAL PROBLEM PHARMACEUTICAL PROBLEM PROBLEM PHARMACEUTICAL PROBLEM PHARMACEUTICAL PH	initial in the condition of the conditio	EUTICAL S PVT. LTD S 2 20mg S	Addition of the property of th	A SARAY STATE OF THE SARAY STATE	h Na in Date in Comp		MD 748 Supt 2021 Supt 2021 Supt 2022 Doc 2022 Sup 36 monthle	3% RM 39 months
Test methods annulared 10°s Autor natural Tables Test methods annulared 10°s Autor Strong, Mornal Tables Ta	inger in the control of the control	REAL TIME ST or 20 mg for 20 mg for 10 mg for	ABILITY STU Impurition, Associated by Parameters and Parameter before out an one of the best before out an one of the best plant on the best plant of the be	DV R DYORT objuston, y and Mal.T. LTS OF ANAL. It imposfus White to off white biconvex	h Na. Date iny Date out of comp	M month	918 918 2021 2022 36 months	39 months
Test me thods munitor ed Limit Limit The control of the control	initial to o off to o off ph in on the open one the open of	6 20 mg fication, Average w fication, Average w go Units, Organic fine boomer Where no off White boomer Millin conted abobes plain on tall oth ades.	Impurition, Assured to the control of the control o	y and MLT. LTS OF ANAL. El months to off White to off Mine one off film coand modes at an one	Barch No. Mig. Date Expliry Date Storage conditions Date of completion VSIS Water to completion VSIS Water to completion	N month	448 2021 2022 36 months	39 Rel 39 months
iffal to off from voc and and do:	initial to ordi	ore peak fication, Average w ge Units, Organic 6 months white to off white becomes the lim control fill on sides.	largerition, Assemble Personal RESU Personals Personals Personal RESU Personals Personal Pers	colution, y and MLT. LTS OF ANAL. 12 months White to off white bionrex film cond	Mfg. Date Expiry Date Storage conditions Date of completion TSIS IS mouths White to off	Z month	2021 2021 4 ± 2°C and 69% + 2022 36 months	39 months
iffal to off to one and and des	initial to co off and to phin on the the the the the the the th	fication, Avongo wage Units, Cryanio financhis	Inpurition, Asm Inpurition, Asm RESU 9 manufas Pano of a Talo of a	tars of ANAL. LTS OF ANAL. 12 months White to off white boor ex film cond film cond orders dain on	Expiry Date Storage conditions Date of completion TSIS B months White to off	M month	2021 2022 2022 36 months	39 months
infail to off stoomer, and phin on des.	initial to to off the phin on the control of the control to the co	6 months 6 months 7 Mine to off 7 Mine borners 8 Mine borners 8 Mine borners 9 Mi	RESU RESU 9 months hine to off hine biconvex m confed	y and MLT. LTS OF ANALY LTS OF ANALY LTS meeting White to off white biconvex film coaned optices than on	Storage conditions Date of completions ISIS 18 months White to off	M most	+ 2°C and 69% + 2022 36 months	5% RH 39 months
Limit India 3 months 6 months When out When out When out When out India 10 months film council f	3 months White to off white beamout fillin on tod tables plan on both acids:		P months Thire to off hite biconvex m confed bices plain on	LTS OF ANALY 12 months White to off white biomes film conted	Date of completion YSIS 18 months White to off	Mmonth	36 months	39 months
Limits Initial 3 menths 6 months white to off white boorners white becomes white becomes white becomes the common film common film common film common the common to the common	3 months White to off white becomes film conted to best ades.	I 	RESU has to off his bionvex m conted bless plain on	LTS OF ANAL I2 months White to off white biconvex film coated solites do n on	IS months White to off	34 months	36 months	39 months
White out of White to off white becomes white becomes white becomes film control fi	3 months White to off white bootest fulls control to both sides	\rightarrow	-	12 menths White to off white biconvex film coated tobless do in on	18 months White to off	34 months	36 months	39 months
When to off When to off White to off When to off white bounest white bounest white bounest with a boune of the owner ow	White to off white becomes film conted tables pain on both ades.			White to off white biconvex film coated tablets than on	White to off			
white biconvex where biconvex white biconvex white biconvex film control film council film control film control tables plan on tables plan on tables plan on both sides. both sides both sides, both sides, both sides. both sides.	white bicomex film conted to bices plain on both ades.			white biomvex film coated tablets tion on				
film control film control film control film control arbitres plain or traffects plain on traffects but adds.	film conted tables plan on both ades.	_		film coated tablets plain on	white biconvex			
non unities plan on unities plan on unities plan on both sides. both ades. both ades.	to both ades.	-		tablets plan on	film coated			
COURSIAN DOWN MICE.	10 H	Ť			tablets plain on			
	of the r peak in		both sades	com sugar.	COLD SIGNS			
В	of the r peak in							
	r poak m							
major peak m major peak m								
_								
ogmin	паобил							
	ay.							
propagation propagation								
8								
_	ou no							
	TABLE 1							
propagam propagam	ar ation							
_	se pour							
o u	and in the							
assery for assery for	y for							
Alorvestation. Alorvestation.	venstatin,							
Average 176.7 mg to 186.56 mg								
T		2 min	1 min	2 min	Imin			




		EMIL	EMIL PHARMACEUTICAL INDUSTRIES PVT. L'	EMIL PHARMACEUTICAL INDUSTRIES PVT. LTD	Reg officer 101 Mangalan, Kalapasali, Barvasi lista februasi 40000, 1924, Tel. et -22-4200200 Kinal integenistrava in	Appendig. Herminal 180,000 night nema in	A late me Cortina Company	Company		
				REAL TIME ST	REAL TIME STABILITY STUDY REPORT	DY R EPORT				
Name of Product			A tory as takin Tab	Tablets 20 mg			But ch No.	8	MD748	
Description of the pack	pack		10's Allu-PVC Bisocr pack	listoer pack			Mfg. Date	0	Oct 2018	
Description of the		There are	Description, Idea	Description, Memilication, Avenge weight, D.T., Dissolution,	e weight, D.T., D.	tesolution,	Expliny Date	80	Sept 2021	
Parameters and Les methods immored		librar coll	Uniformity of Do	Uniformity of Dosage Units, Organic Impunities, Assay and MLT.	tic Impurities, As	any and MLT.	Storage conditions	r	30°C± 2°C and 65% ± 5% RH	5% RH
Date of Initiation			Oct 2018				Date of completion		Dec 2022	
1	W Samuel				RESI	RESULTS OF ANALYSIS	VSE			
ISI		Imiteral	3 months	supurdur 9	9 months	12 months	18 months	24 months	36 months	39 months
		11 94 65%	1 99.42%	1193.54%	11 98.39%	1) 90,78%	119236%			
	NLT80% (Q)	2 93.14%	2 30 05 05 05 05 05 05 05 05 05 05 05 05 05	2 92.08%	2000 SEC. 100 SEC. 10	200230	2 92 13%			
Dissolution	dssolved in 15		4 9 38%	4 90 24%	4 90 60%	4 91 64%	4 91 29%			
	unu	5 93.14%	5190.83%	519031%	5 90.16%	519121%	519022%			
		6 93.57%	6 93.64%	6 93.33%	6 92.75%	6 91 64%	6 90 65%			
	NMT 15.0									
Uniformity of	When									
dom as units	determined on	61								
	to individual									
Organic Impurities										
Ator visitatin Pereli dene Analog	NMT 0.5%	0.077%	56,080.0	0.073%	0.083%	%1600	9,09,00.0			
SOURCE STATE OF THE PARTY OF TH										
Ator vestation Related	NMT 1.0%	0.168%	0.177%	0.172%	0.180%	0.196%	0.210%			
Compound H										
Atox vesteen										
drodo	NMT 0.5%	0.026%	0.030%	0.03.5%	0.039%	0.042%	0.046%			
however also										
A free contraction										
ALOX YESTERNIA										
pytrolocazin 7	NMT 0.5%	Not Detected	Not Detected	Not Detected	Not Detected	Not Detected	Not Detected			
nyd oxymanog										
opory THF	NMT 0.25%	0.010%	0003%	0.019%	0.021%	0.023%	0.02.5%			



ATORVASTATINA COMPRIMIDOS RECUBIERTOS 20 mg










		EMIL	EMIL PHARMACEUTICAL INDUSTRIES PVT. L	PHARMACEUTICAL NDUSTRIES PVT. LTD	Ray office: 111 Many perior Number Many perior Number Many perior Number Approx. Park Number The 4722-Approx. From the School Number Many	Ambail Ambail 1902/30 1964/ama in	As followed the Company Company			
				RAL HAR STABILLT STUDY REPORT	ABILITASIO	DY REPORT			0.000	
CORPORATION OF STREET	-		Altomatism 180 loss 20 mg	NOS ZO INC			March No.	8	00000	I
Description of one purch	PAR.N.		IV SAMPTYCE	manus page			Mary Park	3	60.00	
Parameters and Test methods monitored	st methods mon	parop	Description, Mer Uniformity of D	Description, Memfection, Average weigh, D.T., Dissolution, Uniformity of Data to Units, Occario Imputities, Asser and M.T.	c Impurities, As	section, or and MLT.	Expiry Date Storage conditions	T	30°C ± 2°C and 6.9% ± 9% Ref	-9% RSI
Date of Initiation			Oct 2018				Date of completion	Ī	Dec 2022	
1	4				RESI	RESULTS OF ANALYSIS	VSIS			
Test		midde	3 months	6 months	9 months	12 months	18 months	24 months	36 months	30 months
Dissolution	NLT 80%(Q) dissolved in 15	1] 93.51% 2] 94.16% 3] 92.65% 4] 94.16%	1] 92.91% 2] 93.34% 3] 93.77% 4] 93.59%	1] 93.11% 2] 92.90% 3] 94.40% 4] 92.68%	1] 93.23% 2] 93.02% 3] 92.80% 4] 92.88%	1] 91.88% 2] 92.53% 3] 92.75% 4] 92.75%	1] 93.00% 2] 91.71% 3] 92.14% 4] 91.71%			
	unii.	5) 94.39%	5) 50,77% 6) 24,19%	5] 94.40% 6] 92.90%	5 92.37% 6 92.37%	5 92.33% 6 92.96%	5) 92.14% 6) 91.93%			
Uniformity of desage units	NMT 15.0 When determined on 10 individual units	1.6								
Organic Impurides										
Ato metadin Pyralido no Analog	%\$0.DRN	0.069%	0.07.5%	966.00	9,080.0	0.089%	0.092%			
Atometatin Related Compound H	%01 JMN	0.16.7%	0.174%	0.172%	0.189%	0.195%	0.214%			
Atorvestatin epoxy pytrofoxazin 6 hydroxyanalog	NMT 0.5%	0.021%	0.02.9%	0.031%	0.036%	0.041%	0.046%			
Atorvestatin epocy pytroloceanin 7 hydrocymadog	NMT 0.5%	Not Detected	Not Detected	NotDescrod	Not Detected	Not Detected	Not Detected			
Atorwatatin epoxy THF analog	NMT 0.25%	0.011%	0.01.5%	96100	0.025%	0.031%	0.03.9%			



		M	EMIL	EMIL	Rag office: 1 Mangalam, N Bonnell East, Abonnel, IVID	Ring office: 181 Manzplen, Foldpred, Borvel Serr, Mortes Associe, WICA	**************************************			
		EMIL	INDUSTR	NDUSTRIES PVT. LTD		9900290 milpharma.in	As Did Heriales Conflod Conpany	Company		
				REAL TIME :	REAL TIME STABILLTY STUDY REPORT	DY REPORT				
Name of Product			Atom sets tin Tablets 20 mg	ilons 20 mg			Batch No.	MD749	61	
Description of the pack	te pack		10's Alu-PVC Blisser pack	listor pack			Mfg. Date	Oct 2018	810	
Per anatology and	Per enterior and Total and Bodies and and an analysis and	box office	Description, 1de	Description, Identification, Average weight, D.T., Dissolution,	weight, D.T., De	*connect	Expliry Date	Sept 202	80.21	
		2010000	Uniformity of D	Uniformity of Dosage Units, Organic Impunities, Assay and MLT	ic Impurities, Ass	y and MLT.	Storage conditions	30.00	30°C± 2°C and 69% ±5% RH	5% R.H
Date of Initiation			Oct 2018				Date of completion	Dec 3022	0.22	
Test	Limit				KIN	RESULTS OF ANALYSIS				
		Intial	3 months	6 months	9 months	12 months	18 months	24 months	36 months	39 months
Atometatin related compound D	NMT 035 to 0.5 (if Atorvastatin opexy THF anlog is integrated together)	Na Detected	Not Detected	Not Denoted	Not Denocted	Not Denocted	Not Denocred			
Any other unspection degradation product	NMT 0.2%	%6800	0.096%	%46600	0.11%	0.11%	0.12%			
Total degradation:	NMT 4.0%	950900	0.410%	95000	0.410%	0.42.0%	0.43.9%			
Assay	94.3% to	%8866	93.44.96	%90'66	98.78%	98.64%	98.5.9%			
Microbial Linkt Test	Test									
Total aerolae microbial count	icrosta count						•			
Bacterial	NMT 1000 cdu/g	45 cfulg	क्ष व्यक्ति	30 cfu/g	45 cfu/g	45 cfu/g	S) offu/g			
Fungi	NMT 100 cfu/g	Absent	Absont	Absont	Abson	Absent	Absant			
Test for specifie	est for specified microorganisms:	80								
E. Coll	Absentin 1 g	Absent	Absent	Absent	Absent	Absent	Absent			
Salm onelline	Absentin 10 g	Absent	Absent	Absent	Abson	Absent	Absont			
Pseudomonas	Absentin 1 g	Absent	Absent	Absent	Absent	Absent	Absont			
Stap, Aurous	Absontin 1 g	Absent	Absont	Absont	Absont	Absent	Absent			
Rem	ark: Sublity da	n found settisfactory	up to 18 month 1	Remarks: Sorbility data found sensitionary up to 18 month further stability to be common as per protocol	o configure as per	rotood.		CO CO	Street	sypostol earlan
								To many	PVP	Approved By: Mr. S. M. Deparder
								2	0	QA Manager






	•	[
		EM F	EMIL PHARMACEUTICAL INDUSTRIES PVT. L'	EMIL PHARMACEUTICAL INDUSTRIES PVT. LTD	Managaten, No Ingressol, Managaten, No Ingressol, Borovat Creek, Marebell ADDORS, INCRA, Tel: +91-22-42(900290) Breast info@pressjelesena.in	lipead. Arrbai 90290 sphaream	As Belling and Contact			
	1			REAL TIME ST	REAL TIME STABILITY STUDY REPORT	DY REPORT				
Name of Product			Atoma statis Tab	Tablets 20 mg			Batch No.	W	MD750	
Description of the pack	pack		10's Alu-PVC Blistor pack	itstorr prock			Mrg. Date	ŏ	Oct 20 18	
The same of the sa	The second second second		Description, Idea	Description, Memification, Average weight, D.T., Dissolution,	weight, D.T., D.	seoution.	Expiry Date	8	Sept 2021	
Far atherers and Less the shods monitored	ST TREMOTS HOR	an red	Uniformity of D.	Uniformity of Domge Units, Organic Impurities, Assay and MLT.	ic Impurities, As	ay and MLT.	Storage conditions		30°C ±2°C and 65% ±5% RH	1949,894
Date of Initiation			Oct 2018				Date of completion		Dec 2022	
1	N. Constitution of the Con				RESI	RESULTS OF ANALYSIS	VSIS			
Test	1	minim	3 months	6 months	9 months	12 months	18 months	24 months	36 months	30 months
		11 94 30%	11 94.19%	1] 93.7.6%	1191.35%	119135%	266116 ll			
	NLT80%(Q)	30 02 44%	31 90 70%	31 00 6364	3101366	31013564	30 01 60 66			
Dissolution	dissolved in 15	40 93 51 %	40 03 1254	41 92 2 964	4192.85%	419243%	40 91.84%			
	man	51 94, 16%	51 93 93%	5 92 4/86	5192.63%	5192.00%	5191.19%			
		693.30%	0 94 19%	6] 91.82%	6191.98%	6 91.56%	690.97%			
	NMT 150									
Uniformity of	determined on	0.1								
dosage units	10 individual									
	(min)S									
Organic Impurities										
Atometatin PyralidoreAnalog	NMT 0.5%	0.074%	0.077%	0.084%	0.086%	0.089%	0.092%			
Atometica										
Related	NMT 1.0%	0.160%	0.170%	0.176%	0.181%	0.186%	0.210%			
Compound H										
Atto Prestation										
epoxy	NMT 0.5%	0.027%	0.030%	0.034%	0.036%	0.042%	0.049%			
hydroxymalog										
Ato metadin										
epaxy	NAME O 456	Nor Detected	Nor Detected	Mor Detected	Nor Detected	Nor Deported	Nor Detected			
pytholoxacia 7										
Aro mostoria										
epoxy THF	NB6T 0.25%	0.01.5%	0.01.0%	0.019%	0.021%	0.026%	0.031%			



ATORVASTATINA COMPRIMIDOS RECUBIERTOS 20 mg





ATORVASTATINA COMPRIMIDOS RECUBIERTOS 20 mg **Estudio de estabilidad**

IV. <u>DISCUSIÓN</u>

De acuerdo a los resultados obtenidos en el Estudio de Estabilidad, tanto Acelerado como a Tiempo Real de los lotes MD748, MD749 y MD750 se puede verificar que los lotes estudiados no muestran deterioro físico o químico en el envase utilizado (Blíster ALU/PVC transparente), no se evidencia una disminución significativa en la valoración del activo, y los parámetros analizados se mantuvieron dentro de los límites especificados, durante 6 meses en el estudio acelerado y durante al menos 18 meses en el estudio a tiempo real, el cual sigue en curso.

V. CONCLUSIÓN

Basado en los datos adquiridos de los estudios de estabilidad a tiempo real y acelerado, se concluye provisoriamente que el producto analizado es estable por un periodo de 24 meses si se almacena en su envase original cerrado, a una temperatura no mayor a $30^{\circ}\text{C} \pm 2^{\circ}\text{C}$ y una humedad ambiental de $65\% \pm 5\%$.

VI. ESPECIFICACIÓN DE LA VIDA ÚTIL

Se propone un periodo de eficacia para ATORVASTATINA COMPRIMIDOS RECUBIERTOS 20 mg de 24 meses a partir de su fecha de fabricación almacenándolo en su envase original (Blister ALU/PVC transparente), a una temperatura ambiente no mayor a 30°C ± 2°C, protegido de la humedad y la luz.

